Amicus Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company was acquired and is no longer trading on Nasdaq, ending its time as a public company.
The acquisition that was announced in December 2025 finished, making BioMarin the new owner.
Shareholders voted 99.95% in favor, confirming they supported selling the company to BioMarin.
Shows the company's final year as independent, with financial data through December 31, 2025.
Two main drugs generated this year's sales: Galafold at $522 million and Pombiliti plus Opfolda at $112 million.
Shows the company's financial position that BioMarin acquired, including its drug revenue streams.
Stocky reads Amicus Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Amicus Therapeutics, Inc.'s most recent tracked filing was a 8-K on 27 Apr 2026: Amicus completes merger with BioMarin, exits public markets.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.